Hepatitis C virus (HCV) infects >170 million people worldwide. Although chronic HCV can be treated, it is the leading cause of death in the US among chronic viral infections, resulting in liver fibrosis, cirrhosis, and hepatocellular carcinom (HCC), that are not fully reversed by therapy. HCV is challenging to study: the infected organ (the liver) is not easily accessible, and blood is a small window on infection dynamics; there is no representative tissue culture model; and animal models lack representative immunity. Despite the challenges, chronic HCV infection is an ideal model to study the spread of viruses through solid tissues because i) HCV infection is predominantly constrained to one cell type (hepatocyte), ii) HCV replication is largely at steady state in chronic infection, and iii) within-ost HCV diversity is immense, forming a quasispecies that permits phylogenetic inference of local viral spread. We assembled a multidisciplinary team from Johns Hopkins University (JHU), Los Alamos National Laboratory (LANL) and Lancaster University, UK, that combines complementary skills in translational virology, dynamic viral modeling and spatial statistics. The JHU team has developed unique capabilities to measure HCV infection and sequence variation in single hepatocytes by single-cell laser capture microdissection (scLCM) and has access to a precious repository of liver biopsies from HCV-infected persons. The researchers at LANL have developed models of HCV infection at multiple scales (e.g., intracellular to whole body), and the investigators at Lancaster University are world leaders in spatial statistics. Our hypothesis is that HCV spreads and is constrained locally by a balance between propagation from infected hepatocytes and innate immune control. We will employ scLCM for thousands of cells from HCV-infected people to spatially map HCV replication, diversification, and local immune responses; we will use this data to develop mechanistic models of HCV spread through tissues. We will employ these tools to address the following specific aims.
Aim 1. To characterize in detail infected cell clusters, the intrahepatic HCV RNA landscape, and their relation to serum HCV RNA levels.
Aim 2. To determine if intrahepatic HCV spread occurs due to localized infection rather than due to systemic spread.
Aim 3. To determine if local innate immune responses constrain intrahepatic HCV spread.
Our aims are integrated and innovative, yet feasible. Not only is our strategy important in understanding HCV spread, but can be broadly applied to other chronic infections: indeed our system is an ideal model for such studies. In addition, our approaches open new avenues and provide new tools for future investigations.
Hepatitis C virus (HCV) infects over 170 million people worldwide, causes significant pathology, and is the leading cause of liver transplant in the USA. This project joins clinicians and modelers to develop new insights into chronic HCV infection by building models of disease propagation at the intrahepatic (liver) level.
|Nguyen, Thi Huyen Tram; Guedj, Jérémie; Uprichard, Susan L et al. (2017) The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics? Sci Rep 7:10233|
|Goyal, Ashish; Ribeiro, Ruy M; Perelson, Alan S (2017) The Role of Infected Cell Proliferation in the Clearance of Acute HBV Infection in Humans. Viruses 9:|
|Graw, Frederik; Perelson, Alan S (2016) Modeling Viral Spread. Annu Rev Virol 3:555-572|